IBBQ
Invesco Nasdaq Biotechnology ETF
IBBQ tracks a modified market-cap-weighted index of US biotechnology and pharmaceutical companies listed on the NASDAQ.
US
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 48.0 M
ASSETS UNDER MGMT
19 bp
EXPENSES
Fund Basics
| Inception date | Jun 11, 2021 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Quarterly |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| AMGEN INC | 7.6 % |
| VERTEX PHARMACEUTICALS INC | 7.6 % |
| GILEAD SCIENCES INC | 7.4 % |
| REGENERON PHARMACEUTICALS | 5.5 % |
| ALNYLAM PHARMACEUTICALS INC | 5.3 % |
| ASTRAZENECA PLC-SPONS ADR | 3.9 % |
| INSMED INC | 3.0 % |
| ARGENX SE ADR | 2.2 % |
| BIOGEN IDEC INC | 2.1 % |
| UNITED THERAPEUTICS CORP | 1.8 % |
Constituent Breakdown
| Number of holdings | 207 |
| Herfindahl-Hirschman Index | 301 |
| Wgt avg mkt cap (mns) | $60,767 |
| Large cap (>$10bn) | 69.1% |
| Mid cap ($2-10bn) | 15.8% |
| Small cap (<$2bn) | 9.1% |
| Developed mkts. | 93.5% |
| Emerging mkts. | 1.2% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 79.1 % |
 |
BRITAIN | 5.2 % |
 |
NETHERLANDS | 3.1 % |
 |
IRELAND | 1.3 % |
 |
DENMARK | 1.2 % |
 |
FRANCE | 1.2 % |
 |
CHINA | 1.2 % |
 |
GERMANY | 1.1 % |
 |
SWITZERLAND | 0.6 % |
Historical Performance
Standardized Performance (as of 05/31/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 5.1% | 46.4% | 16.4% | 13.5% | -- | -- | -- | 3.1% |
| Dividend Yield | 0.1% | 1.5% | 1.2% | 1.1% | -- | -- | -- | 0.9% |
| Total Returns | 5.2% | 47.9% | 17.6% | 14.6% | -- | -- | -- | 4.1% | Ann. Volatility | 21.9% | 19.4% | 21.0% | 19.7% | -- | -- | -- | 21.8% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.88 | 28% |
| MSCI EAFE | 0.75 | 34% |
| MSCI Emg Mkts | 0.47 | 23% |
Liquidity Measures
| Avg. volume (000) | 19 |
| ADV traded (mns) | $1 |
| Turnover | 1.2% |
| Avg. Bid/Ask (% of price) | 0.18% |
Technical Indicators
| 30d moving avg. (EMA) | $29.38 |
| Relative strength (RSI) | 53 |
| MACD/Signal | 0.06/0.00 |
| Bollinger Bands (Upper/Lower) | $30.27/$28.52 |
| Short interest (% of AUM) | 7.4% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. IBBQ |
Expenses vs. IBBQ |
ALTAR Score™ vs. IBBQ |
|---|---|---|---|---|
| IBB | iShares Biotechnology ETF | 71.8% | +26 bp | -0.9% |
| BBH | VanEck Biotech ETF | 49.7% | +16 bp | +4.3% |
| PBE | Invesco Biotechnology & Genome ETF | 34.8% | +39 bp | +2.7% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 34.6% | +41 bp | +7.2% |
| XBI | State Street SPDR S&P Biotech ETF | 34.1% | +16 bp | -0.4% |
| BBP | Virtus LifeSci Biotech Products ETF | 33.6% | +60 bp | -4.1% |
| FBT | First Trust NYSE Arca Biotechnology Index Fund | 32.7% | +37 bp | +1.5% |
| BMED | Future Health ETF | 25.1% | +66 bp | +0.7% |
| HELX | Franklin Genomic Advancements ETF | 24.3% | +31 bp | -1.3% |
| WDNA | WisdomTree BioRevolution Fund | 22.8% | +26 bp | -3.2% |
Risk and Returns: IBBQ vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 5/30/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
0.3%
ALTAR SCORE™
1st
PERCENTILE
AVOID
ETFRC RATING
There are 1,400 funds in the US Equity category with an average
ALTAR Score™ of 5.3% and a standard deviation
of 2.1%. IBBQ's ALTAR Score™ is approximately -2.3 standard
deviations above the category average. This places IBBQ in the 1st percentile
among funds in the category.
Sell-Side Consensus
$36.69
PRICE TARGET
+23.0%
UPSIDE